Development of immunosorbents for apoB-containing lipoproteins apheresis.
Three types of sorbents were developed for the specific removal of atherogenic apoB-containing low-density lipoprotein (LDL) and lipoprotein LDL (a) (Lp[a]) from human plasma. Two sorbents contained monospecific sheep polyclonal or mouse monoclonal antibodies against human apoprotein B-100. The third one was intended for specific removal of Lp(a) and contains sheep antibodies against human Lp(a). Thirty patients were treated for up to 9 years by LDL apheresis with anti-LDL immunosorbents. A pilot study of Lp(a) apheresis with 3 patients was conducted during 3 years. The results showed that extracorporeal immunosorption is safe and effective for lowering LDL and Lp(a). These procedures may be used both for metabolic investigations and for studies on possible regression of atherosclerosis.
Pokrovsky
S N
SN
Institute of Experimental Cardiology, Cardiology Research Center, Moscow, Russia.
Sussekov
A V
AV
Adamova
I Y
IY
Afanasieva
O I
OI
Benevolenskaya
G F
GF
Konovalov
G A
GA
Kukharchuk
V V
VV
D000293:Adolescent; D000328:Adult; D000818:Animals; D000906:Antibodies / Q000276:immunology / Q000378:metabolism; D001055:Apolipoproteins B / Q000097:blood* / Q000276:immunology; D001781:Blood Component Removal; D002648:Child; D017023:Coronary Angiography; D004797:Enzyme-Linked Immunosorbent Assay; D005260:Female; D005340:Fibrinogen / Q000032:analysis; D006801:Humans; D006937:Hypercholesterolemia / Q000628:therapy*; D007163:Immunosorbent Techniques; D007164:Immunosorbents / Q000276:immunology / Q000627:therapeutic use; D017270:Lipoprotein(a) / Q000097:blood*; D008077:Lipoproteins, LDL / Q000097:blood*; D008137:Longitudinal Studies; D008297:Male; D051379:Mice; D008875:Middle Aged; D010865:Pilot Projects; D010958:Plasminogen / Q000032:analysis; D012756:Sheep
D000906:Antibodies; D001055:Apolipoproteins B; D007164:Immunosorbents; D017270:Lipoprotein(a); D008077:Lipoproteins, LDL; D005340:Fibrinogen; D010958:Plasminogen